IRAK4 and Alzheimer disease: In HS and AD patients, KT‐474 not only achieved similar blood IRAK4 degradation effects but also normalized overexpressed IRAK4 levels in skin lesions and significantly improved disease‐related inflammatory biomarkers [313].